MX2023000164A - Métodos y composiciones para tratar la hemofilia. - Google Patents

Métodos y composiciones para tratar la hemofilia.

Info

Publication number
MX2023000164A
MX2023000164A MX2023000164A MX2023000164A MX2023000164A MX 2023000164 A MX2023000164 A MX 2023000164A MX 2023000164 A MX2023000164 A MX 2023000164A MX 2023000164 A MX2023000164 A MX 2023000164A MX 2023000164 A MX2023000164 A MX 2023000164A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating hemophilia
hemophilia
patients
Prior art date
Application number
MX2023000164A
Other languages
English (en)
Spanish (es)
Inventor
Baisong Mei
Shauna Andersson
Qifeng Yu
Pronabesh Dasmahapatra
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2023000164A publication Critical patent/MX2023000164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MX2023000164A 2020-06-22 2021-06-22 Métodos y composiciones para tratar la hemofilia. MX2023000164A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063042390P 2020-06-22 2020-06-22
PCT/US2021/038445 WO2021262695A1 (en) 2020-06-22 2021-06-22 Methods and compositions for treating hemophilia

Publications (1)

Publication Number Publication Date
MX2023000164A true MX2023000164A (es) 2023-07-06

Family

ID=76943130

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000164A MX2023000164A (es) 2020-06-22 2021-06-22 Métodos y composiciones para tratar la hemofilia.

Country Status (12)

Country Link
US (2) US20210393669A1 (https=)
EP (1) EP4168018A1 (https=)
JP (1) JP2023531679A (https=)
KR (1) KR20230027277A (https=)
CN (1) CN115942940A (https=)
AU (1) AU2021296786A1 (https=)
BR (1) BR112022026265A2 (https=)
CA (1) CA3188137A1 (https=)
IL (1) IL299295A (https=)
MX (1) MX2023000164A (https=)
TW (1) TW202216172A (https=)
WO (1) WO2021262695A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240075001A1 (en) * 2022-05-24 2024-03-07 Darren Rubin Methods to reduce hemorrhage and mortality on the battlefield and applications for trauma patients
US20240000744A1 (en) * 2022-06-08 2024-01-04 Genzyme Corporation Treatment of Hemophilia with Fitusiran
CN118460655B (zh) * 2024-07-10 2025-01-28 凯莱英医药集团（天津）股份有限公司 抑制FXI基因表达的siRNA的制备方法
WO2026012399A1 (zh) * 2024-07-10 2026-01-15 正大天晴药业集团股份有限公司 靶向serpinc1的双链核糖核酸

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
KR20180095843A (ko) 2015-12-07 2018-08-28 젠자임 코포레이션 Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
TW202434265A (zh) * 2017-07-10 2024-09-01 美商健贊公司 於患有血友病之個體中治療出血事件之方法及組成物

Also Published As

Publication number Publication date
WO2021262695A1 (en) 2021-12-30
KR20230027277A (ko) 2023-02-27
BR112022026265A2 (pt) 2023-01-17
JP2023531679A (ja) 2023-07-25
TW202216172A (zh) 2022-05-01
AU2021296786A1 (en) 2023-02-23
CN115942940A (zh) 2023-04-07
IL299295A (en) 2023-02-01
CA3188137A1 (en) 2021-12-30
US20260014188A1 (en) 2026-01-15
US20210393669A1 (en) 2021-12-23
EP4168018A1 (en) 2023-04-26

Similar Documents

Publication Publication Date Title
MX2023000164A (es) Métodos y composiciones para tratar la hemofilia.
CL2023002090A1 (es) Inhibidores de kras tricíclicos fusionados
CO2025015814A2 (es) Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
CL2020002146A1 (es) Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer.
MX2024014142A (es) Novedosos inhibidores de molecula peque?a de factores de transcripcion tead
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
MX379543B (es) Purinonas como inhibidores de proteasa específica de ubiquitina 1.
CR20240120A (es) Compuesto inductor de la degradación de PLK1 novedoso
BR112022023025A2 (pt) Moduladores de htt para tratar doença de huntington
JOP20230157A1 (ar) طرق مُعالجة فيروس كورونا
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
CO2022000481A2 (es) Inhibidores de enzimas
CR20140113A (es) Imidazopiridazinas sustituidas con amino
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
PE20230180A1 (es) Uso de bi853520 en tratamiento contra el cancer
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2024002391A (es) Inhibidores de indolina de kif18a.
MX2022014925A (es) Moduladores de il-17a.
MX2022000811A (es) Inhibidores de enzimas.
MX2024003529A (es) Metodos y composiciones para el tratamiento de la enfermedad renal poliquistica.
BR112022008938A2 (pt) Derivados de 1-aminossulfonil-2-carboxipirrol como inibidores de metalo-beta-lactamase
MX2024010344A (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa
UY39434A (es) Nuevos compuestos
MX2023006231A (es) Inhibidores de enzimas.